JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Scope & Guideline
Empowering the global fight against cancer with open access.
Introduction
Aims and Scopes
- Cancer Biology and Mechanisms:
Research exploring the molecular and cellular mechanisms underlying cancer development, progression, and metastasis, including studies on gene expression, epigenetic modifications, and tumor microenvironment interactions. - Therapeutic Strategies and Drug Development:
Investigations into novel therapeutic agents, including small molecules, biologics, and combination therapies, aimed at enhancing the efficacy of existing treatments and overcoming drug resistance. - Clinical Trials and Patient-Derived Models:
Studies involving clinical trials for new cancer therapies, as well as the development and use of patient-derived tumor models (such as organoids) to personalize treatment strategies. - Immunotherapy and Immune Microenvironment:
Research focused on the role of the immune system in cancer, including the development of immunotherapeutic approaches, immune checkpoint inhibitors, and the characterization of tumor-infiltrating lymphocytes. - Biomarkers and Liquid Biopsy:
Exploration of novel biomarkers for early cancer detection, monitoring treatment response, and predicting clinical outcomes, including the use of liquid biopsy techniques to analyze circulating tumor DNA. - Metabolism and Cancer:
Studies examining the metabolic reprogramming of cancer cells, including the impact of metabolic pathways on tumor growth, metastasis, and treatment resistance. - Cancer Stem Cells and Tumor Heterogeneity:
Research on cancer stem cells, their role in tumor initiation and progression, and the heterogeneity of tumor cell populations that contribute to treatment challenges.
Trending and Emerging
- Targeted Therapies and Personalized Medicine:
A growing number of studies focus on targeted therapies that are tailored to individual patient profiles, driven by genetic, epigenetic, or molecular markers, signaling a shift towards precision oncology. - Immunotherapy Advances:
There is an increasing emphasis on immunotherapies, including checkpoint inhibitors and CAR T-cell therapies, highlighting the importance of harnessing the immune system to combat cancer. - Liquid Biopsy and Circulating Biomarkers:
Research into liquid biopsy techniques and circulating tumor DNA as non-invasive methods for early cancer detection, monitoring treatment response, and understanding tumor dynamics is gaining momentum. - Metabolic Reprogramming in Cancer:
Emerging evidence supports the significance of altered metabolic pathways in cancer cells, with studies exploring how these changes contribute to tumor growth and resistance to therapies. - Tumor Microenvironment Interactions:
An increased focus on the interactions between tumor cells and their microenvironment, including the role of stromal cells, immune cells, and extracellular matrix components in cancer progression and therapy response. - Nanotechnology in Cancer Therapy:
Innovative applications of nanotechnology for drug delivery systems, enhancing the precision and effectiveness of cancer therapies, are becoming a prominent area of research. - Role of Non-Coding RNAs:
Investigations into the functions of non-coding RNAs, including long non-coding RNAs and circular RNAs, in tumor biology and their potential as therapeutic targets or biomarkers are on the rise.
Declining or Waning
- Traditional Chemotherapy Approaches:
There has been a noticeable decline in studies solely focused on traditional chemotherapy regimens without integration of novel agents or combinatorial approaches, as the field shifts towards more personalized and targeted therapies. - Single-Agent Studies:
Research focusing exclusively on single-agent therapies is waning, with a greater emphasis now on combination therapies that leverage synergistic effects to improve treatment outcomes. - Basic Cancer Biology without Translational Focus:
Studies that explore basic cancer biology without a clear translational application or clinical relevance are less frequently published, as the journal increasingly prioritizes research that connects laboratory findings to clinical implications. - Exploratory Studies with Limited Clinical Relevance:
There is a decline in exploratory studies that do not provide direct insights or applications for clinical practice, as the journal emphasizes findings that can be directly translated into therapeutic strategies.
Similar Journals
ONCOGENE
Unraveling the Mysteries of Cancer BiologyONCOGENE is a premier peer-reviewed journal published by SpringerNature, serving as a crucial platform for innovative research within the fields of Cancer Research, Genetics, and Molecular Biology. With an impressive Impact Factor and a distinguished Q1 ranking across major categories, ONCOGENE publishes cutting-edge studies aimed at unraveling the complexities of cancer biology and genetic mechanisms. The journal has been a vital resource for the academic community since its inception in 1987, and it continues to foster rigorous scientific discussions and collaborations. Researchers, professionals, and students can access a wealth of critical insights and advances in cancer genomics and therapeutic approaches, cementing ONCOGENE’s role as a leading voice in the landscape of biomedical research. For comprehensive academic research, ONCOGENE remains an indispensable source of knowledge with contributions that significantly impact the evolution of cancer research and treatment strategies.
ONCOLOGY RESEARCH
Elevating Knowledge in the Fight Against CancerONCOLOGY RESEARCH, published by TECH SCIENCE PRESS, is a vital academic journal dedicated to the rapidly evolving field of oncology. With its ISSN 0965-0407 and E-ISSN 1555-3906, the journal serves as a key resource for researchers, clinicians, and academicians committed to advancing cancer research and treatment strategies. Operating without an Open Access model, ONCOLOGY RESEARCH provides high-quality, peer-reviewed articles that cover diverse topics within cancer research, medicine, and oncology, with its 2023 Scopus ranking placing it in the Q3 quartile. The journal's commitment to facilitating rigorous scientific discourse is evident in its historical breadth, with a publishing history dating back to 1992. ONCOLOGY RESEARCH is not only significant for the academic community but also plays a critical role in fostering new insights and approaches in the fight against cancer, making it a must-read for those involved in this critical area of study.
NEOPLASMA
Deepening Understanding of Neoplastic MechanismsNEOPLASMA is a prominent journal published by AEPRESS SRO, dedicated to the multifaceted field of oncology and cancer research. Since its inception in 1957, this esteemed publication has served as a vital platform for advancing the understanding of neoplastic diseases, disseminating high-quality research findings that contribute to clinical and laboratory advancements. Operating under a robust framework of peer review, NEOPLASMA holds significant credibility, as evidenced by its Q2 ranking in the Medicine (miscellaneous) category and Q3 rankings in both Cancer Research and Oncology for 2023. Furthermore, with an ISSN of 0028-2685 and E-ISSN 1338-4317, the journal fosters accessibility to valuable scientific content despite the absence of open access options. Positioned in Bratislava, Slovakia, NEOPLASMA continues to attract a global readership, making substantial contributions to the fields of biochemistry, genetics, and molecular biology as highlighted by its Scopus rankings. This journal is essential reading for researchers, professionals, and students looking to stay abreast of the latest developments in cancer research and treatment strategies.
BRITISH JOURNAL OF CANCER
Shaping the Future of Oncology Through Quality Scholarship.The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
Pioneering Insights in Oncology and GeneticsBIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, published by Elsevier, has established itself as a leading journal in the domains of cancer research, genetics, and oncology, holding a prestigious position in the Q1 quartile rankings in these fields as of 2023. With an ISSN of 0304-419X and an E-ISSN of 1879-2561, this journal aims to disseminate high-quality, impactful reviews that synthesize the latest advancements and findings in cancer biology, treatment modalities, and genomic studies. Its robust indexing and remarkable Scopus rankings—placing it in the 95th to 91st percentiles across various categories—underline its significance for researchers, clinicians, and students passionate about oncology. Operating from its Netherlands headquarters, BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER is dedicated to fostering a comprehensive understanding of the complex biological mechanisms underlying cancer, promoting innovative therapeutic strategies, and guiding future research directions.
Oncologie
Elevating oncology research to new heights.Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.
Molecular Cancer
Leading the charge in innovative cancer solutions.Molecular Cancer, published by BMC, stands as a premier open access journal dedicated to advancing our understanding of cancer biology, treatment, and prevention since its inception in 2002. With an impressive Q1 ranking in the domains of Cancer Research, Molecular Medicine, and Oncology, this journal occupies a significant position in the academic landscape, emphasizing high-quality research that influences clinical practices and future studies. The journal is indexed in leading databases with exceptional Scopus ranks, reflecting its rigorous peer-review process and impactful contributions to the field, where it ranks in the top 2-3 positions across various relevant categories. Based in the United Kingdom, Molecular Cancer offers researchers worldwide a valuable platform for disseminating innovative findings that drive the biomedical community forward. The journal's open access model ensures that groundbreaking research is freely accessible, fostering collaboration and knowledge sharing among professionals, students, and academics alike. Explore cutting-edge developments in cancer research through Molecular Cancer and join a community committed to improving patient outcomes and advancing scientific discovery.
CANCER IMMUNOLOGY IMMUNOTHERAPY
Unraveling the Complexities of Immunology and OncologyCancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.
Cancer Communications
Advancing the Frontiers of Cancer ResearchCancer Communications, published by WILEY, is a leading open-access journal that has positioned itself at the forefront of cancer research and oncology since its inception in 2017. With an impressive HIndex reflective of its scholarly impact and recognized in the Q1 category for both Cancer Research and Oncology as of 2023, this journal consistently ranks in the top echelons of its field, specifically at Rank #16/404 and Rank #13/230 in their respective categories on Scopus. Cancer Communications aims to disseminate cutting-edge research findings, innovative methodologies, and significant advancements in cancer treatments, thereby fostering a deeper understanding of oncology among researchers, healthcare professionals, and students. The journal operates under an Open Access model since 2018, ensuring that vital research is accessible to a global audience, thus enhancing collaboration and knowledge sharing necessary to tackle one of the most pressing health challenges of our time. Located in Hoboken, NJ, United States, and with a strong commitment to scientific excellence, Cancer Communications remains an essential resource for anyone engaged in the fight against cancer.
CURRENT CANCER DRUG TARGETS
Advancing targeted therapies for a cancer-free tomorrow.CURRENT CANCER DRUG TARGETS is a prominent academic journal published by Bentham Science Publishers Ltd, focusing on the critical intersection of cancer research and innovative drug development. Since its inception in 2001, this journal has offered a platform for the dissemination of cutting-edge research aimed at advancing targeted cancer therapies, contributing significantly to the fields of Cancer Research, Drug Discovery, Oncology, and Pharmacology. With a respectable impact factor and consistent ranking in its respective categories, including Q2 in Drug Discovery and Pharmacology, it positions itself as an invaluable resource for researchers, clinicians, and students alike. CURRENT CANCER DRUG TARGETS is dedicated to enhancing our understanding of novel therapeutic targets and methods, thereby fostering a collaborative environment for knowledge exchange in the ever-evolving landscape of cancer treatment.